{
    "Trade/Device Name(s)": [
        "UCP Home Drug Screening Test Cups",
        "UCP Home\u2122 Drug Screening Test Cups"
    ],
    "Submitter Information": "UCP Biosciences, Inc.",
    "510(k) Number": "k122419",
    "Predicate Device Reference 510(k) Number(s)": [
        "k091588",
        "k072062",
        "k110515"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ",
        "DIO",
        "DIS",
        "JXM",
        "DJC",
        "DJR",
        "DJG",
        "LCM",
        "LDJ",
        "LFG"
    ],
    "Summary Letter Date": "November 2, 2012",
    "Summary Letter Received Date": "November 6, 2012",
    "Submission Date": "November 30, 2012",
    "Regulation Number(s)": [
        "21CFR862.3100",
        "21CFR862.3150",
        "21CFR862.3170",
        "21CFR862.3250",
        "21CFR862.3610",
        "21CFR862.3620",
        "21CFR862.3650"
    ],
    "Regulation Name(s)": [
        "Amphetamine Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Barbiturates",
        "Benzodiazepines",
        "Cocaine",
        "Marijuana",
        "Methadone",
        "Methamphetamine",
        "MDMA",
        "Morphine",
        "Opiates 2000",
        "Oxycodone",
        "Phencyclidine",
        "Tricyclic Antidepressant",
        "D-Amphetamine",
        "Secobarbital",
        "Oxazepam",
        "Benzoylecgonine",
        "Delta-9-THC-COOH",
        "Nortiptyline"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunochromatographic assay",
        "Competitive binding immunoassay"
    ],
    "Methodologies": [
        "Qualitative detection",
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Panel"
    ],
    "Document Summary": "FDA 510(k) summary for UCP Home Drug Screening Test Cups, qualitative lateral flow immunoassays for detection of multiple drugs and metabolites in urine for OTC and professional use",
    "Indications for Use Summary": "Intended for rapid, qualitative detection of listed drugs and metabolites in human urine as a first step for OTC and professional use; preliminary results should be confirmed by other methods such as GC/MS.",
    "fda_folder": "Toxicology"
}